Introduction {#S0001}
============

Hidradenitis suppurativa (HS), which has an estimated worldwide prevalence of 1%, is a chronic inflammatory follicular occlusive disease predominantly involving the intertriginous areas.[@CIT0001] Clinically, its manifestations vary from inflammatory nodules and abscesses to the formation of sinus tracts and scarring.[@CIT0002] It has a profound adverse impact on patients' quality of life, and has been closely linked with physical and psychiatric co-morbidities including obesity, hypertension, dyslipidemia, diabetes mellitus, thyroid disorders, polycystic ovarian syndrome, arthropathies and depression.[@CIT0003]

Pathophysiology of HS {#S0002}
=====================

Histopathological examination of early lesions in HS demonstrates terminal follicular hyperkeratosis, hyperplasia of the follicular epithelium and perifolliculitis. The occlusion of the terminal hair follicle results in dilation and cyst formation, followed by rupture of the hair follicle. The introduction of follicular contents to the surrounding dermis induces an inflammatory response and subsequent formation of abscess, sinus tracts, fibrosis and scars. This is worsened by biofilm formation and secondary infection.[@CIT0004],[@CIT0005]

The inflammatory response in HS has in recent years been better characterized, although there are many components that remain to be elucidated. In particular, tumor necrosis factor (TNF)-α, IL-1β, IL-10, and the IL-23/T-helper (Th) 17 and IL-12/Th1 pathways play key roles in immune dysregulation in HS.[@CIT0006],[@CIT0007] In studies of HS skin, significantly increased frequencies of CD4 T cells expressing Th17-associated cytokines and TNF were found infiltrating HS skin.[@CIT0007] Treatment with TNF inhibitors was also related with a significant decrease in IL-17 expressing CD4 T cells in HS skin.[@CIT0007]

Staging of HS and implications on therapy {#S0003}
=========================================

HS has traditionally been staged according to the Hurley staging system, first proposed in 1989 ([Table 1](#T0001){ref-type="table"}).[@CIT0008]Table 1Hurley staging of HSStage I (mild)Abscess formation, single or multiple, without sinus tracts and cauterization.Stage II (moderate)Recurrent abscesses with tract formation and cicatrization, single or multiple, widely separated lesions.Stage III (severe)Diffuse or near-diffuse involvement, or multiple interconnected tracts and abscesses across the entire area.[^1][^2]

The Hurley staging system remains useful for determining the severity of disease in individual patients but is limited in monitoring the dynamic characteristics of disease in clinical trials.[@CIT0009] Hence, alternative scoring systems have been developed to better evaluate the efficacy of the intervention, as shown in [Table 2](#T0002){ref-type="table"}.Table 2Scoring systems used in grading HS severityHiSCR[@CIT0099]≥50% reduction in inflammatory lesion count (abscesses and inflammatory nodules)\
**AND**\
No increase in abscesses or draining fistulas compared to baselineHS-PGA[@CIT0011]ClearNo inflammatory or non-inflammatory nodulesMinimalOnly the presence of non-inflammatory nodulesMild1--4 inflammatory nodules\
OR\
1 abscess or draining fistula AND no inflammatory nodulesModerate≥5 inflammatory nodules OR\
1 abscess or draining fistula AND ≥1 inflammatory nodules\
OR\
2--5 abscesses or draining fistulas AND \<10 inflammatory nodulesSevere2--5 abscesses or draining fistulas AND ≥10 inflammatory nodulesVery Severe\>5 abscesses or draining fistulasmSS[@CIT0100]**ANumber of regions affected (3 points per region**):\
Right axilla\
Left axilla\
Right groin\
Left groin\
Right gluteal region\
Left gluteal region\
Other region**BFor [each]{.ul}**...:\
Nodule: 1 point\
Fistula: 6 points**CFor [each]{.ul} affected region, longest distance between two relevant lesions**:\
\<5 cm: 1 point\
5--10 cm: 3 points\
\>10 cm: 9 points**DFor [each]{.ul} affected region**:\
If lesions not clearly separated by normal skin: 9 pointsThe mSS is the total of the subtotals of A to D.HSSI[@CIT0101]Points scoredNo. of sitesBSA affected (%)No. of lesions (erythematous, painful)Drainage (dressing changes per working or leisure hour)Pain (VAS)000000--11111222--32--312--4334--54--5\>15--74≥4\>5\>58--10Sites: Left armpit, right armpit, left side of chest, right side of chest, left groin, right groin, perianal area, sacral area and perineal area.\
The HSSI is the total of all five assessed domains, with a minimum score of 0 and a maximum score of 19.IHS4[@CIT0102]**A**Number of nodules**B**Number of abscesses**C**Number of draining tunnelsThe IHS4 is derived by the formula: **A** x 1+ **B** x 2+ **C** x 4[^3]

Conventional medical therapy, involving oral antibiotics and topical treatments, is suitable for treatment of mild to moderate HS. However, there are patients where HS remains resistant to conventional treatment. With the discovery of the key inflammatory mediators in HS, the role of biologics and other immunomodulatory therapies in the targeted treatment of moderate-to-severe HS has been closely studied. Of these, adalimumab remains the only Food and Drug Administration (FDA)-approved biologic for the treatment of HS.[@CIT0010]

We present a review of all biologics and immunomodulatory therapies that have been reported in the treatment of HS.

Methods {#S0004}
=======

A review of the literature was conducted by multiple PubMed searches using the keywords "hidradenitis suppurativa" or "acne inversa"; with publication date limits from 1 January 1947 to 31 December 2018. Retrieved references were critically appraised. The inclusion criteria were original articles, reports and letters in the English language reporting the treatment of HS with biologic or other immunomodulatory agents, either alone or in combination with conventional drugs or surgery. Articles which were judged to be irrelevant based on the title, abstract or full text, were excluded from the review.

A search of the website Clinicaltrials.gov for planned, in-progress, terminated and completed clinical trials with the terms "hidradenitis suppurativa" and "acne inversa" was also performed up to 31 December 2018.

Results {#S0005}
=======

A total of 2,088 articles were retrieved by multiple PubMed searches conducted until 31 December 2018 using the keywords "hidradenitis suppurativa" or "acne inversa". A total of 107 relevant articles were included in the analysis. A total of 47 case reports, 29 case series, 3 retrospective analyses, 4 cohort studies and 24 articles based on clinical trial data, were selected ([Figure 1](#F0001){ref-type="fig"}).Figure 1Selection of articles identified by PubMed search.

A total of 65 clinical trials were retrieved by a search of the Clinicaltrials.gov database conducted on 31 December 2018, of which 35 were related to immunomodulatory treatment. Twenty of these studies were completed or terminated. To access the results of these trials, the articles retrieved from the PubMed searches were reviewed and matched to their respective clinical trials, using the National Clinical Trial identifier, and the PubMed database was again searched using the terms ("hidradenitis suppurativa" OR "acne inversa") and the medication name. Fourteen of the completed or terminated studies had published articles on PubMed ([Figure 2](#F0002){ref-type="fig"}). When trial results were not available in PubMed, results posted on Clinicaltrials.gov were used. In five cases, the trials were listed as "completed" on Clinicaltrials.gov, but neither PubMed indexed journal articles nor posted study results on Clinicaltrials.gov were found. A World Wide Web search was then performed to retrieve any study results available.Figure 2Selection of articles identified by [[Clinicaltrials.gov search](https://clinicaltrials.gov/)]{.ul}.

Biologic and other immunomodulatory therapies {#S0006}
=============================================

A total of 19 biologic and other immunomodulatory agents reported in the treatment of HS were identified and categorized according to their mode of action ([Table 3](#T0003){ref-type="table"}). Of these, efalizumab has been withdrawn and was thus excluded from this review. Information from individual published articles included in this review is available in [Table 4](#T0004){ref-type="table"}.Table 3Biologics and other immunomodulatory therapies reported in the treatment of HSTNF-α inhibitorsAdalimumab\*[@CIT0010],[@CIT0012],[@CIT0014]--[@CIT0016],[@CIT0023]--[@CIT0027]\
Infliximab[@CIT0009],[@CIT0031],[@CIT0032]\
Etanercept[@CIT0051]\
Golimumab[@CIT0053],[@CIT0054]\
Certolizumab[@CIT0056]IL-1 inhibitorsAnakinra[@CIT0058],[@CIT0060],[@CIT0103]\
Canakinumab[@CIT0062],[@CIT0063]\
Bermekimab[@CIT0066]\
MEDI8968[@CIT0070]IL-12/-23 inhibitorsUstekinumab[@CIT0072]IL-17 inhibitorsSecukinumab[@CIT0074]-[@CIT0076]\
CJM112[@CIT0079]\
Bimekizumab[@CIT0082]IL-23 inhibitorsGuselkumab[@CIT0084]-[@CIT0086]Selective PDE-4 inhibitorsApremilast[@CIT0089],[@CIT0090],[@CIT0104]Complement C5a inhibitorsIFX-1[@CIT0091]--[@CIT0093]CD-11a inhibitorsEfalizumab\*\*[@CIT0105]CD-20 inhibitorsRituximab[@CIT0095]JAK-1 inhibitorsINCB054707[@CIT0096],[@CIT0097][^4][^5][^6] Table 4Articles included in systematic reviewCase reports, case series and retrospective studies**Case reportsStudySubject characteristicsTherapiesDoseTreatment durationEfficacyComplications**Koilakou S et al[@CIT0106]One 38-year-old maleADA40 mg EOWNRNoNoneBenhadou F et al 2018[@CIT0022]One 55-year-old femaleADA160 mg once1 weekYesErythrodermaVan der Zee HH et al 2013[@CIT0053]One 51-year-old femaleADA, GOL, ANKADA 40 mg EOW, GOL 50 mg monthly, ANK 100 mg monthlyADA for 2 years, GOL for 1 year, ANK for 1 yearAll ineffectiveNoneMoul DK et al 2006[@CIT0107]One 67-year-old maleADA40 mg EOW5 monthsYesNoneHarde V et al 2008[@CIT0108]One 32-year-old maleADA80 mg once, then 40 mg weekly6 monthsYesNonede Wet J et al 2017[@CIT0017]One 42-year-old maleADA160 mg at week 0, 80 mg at week 2, and 40 mg weekly for 5 weeks8 weeksYesNoneSamycia M et al[@CIT0109]One 48-year-old maleETA, INF, ADAETA 50 mg weekly, then twice weekly, INF 5 mg/kg, then 10 mg/kg every 6 weeks, ADA\
80 mg at week 0 then 40 mg EOW then weeklyETA for 4 months, INF for 1 year 6 months,\
ADA for 1 yearNo\
Yes, for 1 year\
YesFatigue (from INF)Diamantova et al 2014[@CIT0110]One 50-year-old femaleADA80 mg at week 0 then 40 mg EOW8 weeksYesNoneBosnić et al 2016[@CIT0111]One 39-year-old maleADA40 mg EOW1 yearYesNoneSaraceno et al 2015[@CIT0018]One 50-year-old maleADA40 mg EOW36 weeksYesNoneBessaleli et al 2018[@CIT0112]One 33-year-old femaleADA40 mg, then increased to 80 mg weekly8 monthsYesCervical squamous cell carcinoma in situCrowley EL et al 2018[@CIT0113]One 32-year-old maleADA80 mg at week 0 and then 40 mg weekly3 yearsYesOral candidiasisMolina-Leyva et al 2018[@CIT0114]One 39-year-old femaleADANR16 weeksDLQI reduced from 18 to 0 at week 4 and 16NoneGorovoy et al 2009[@CIT0115]One 47-year-old femaleINF, ADAINF NR, ADA 40 mg EOW15 months for each biologicInitial response for INF, good response for ADAInfusion reaction with urticaria (INF)Murphy et al 2015[@CIT0019]One 26-year-old femaleINF, ADAINF 5 mg/kg for 2 doses, ADA 160 mg/80 mg then 40 mg EOWINF NR, ADA for\
2 monthsResponse to bothDrug hypersensitivity (INF)Friedman et al 2018[@CIT0013]One 48-year-old femaleANK100 mg/day for 9 months, then 200 mg/day for 15 months24 monthsModerate responseDrug-induced sarcoidosisZarchi et al 2013[@CIT0116]One 37-year-old femaleANK200 mg/day1 yearYesStaphylococcus aureus pustular folliculitisJaeger T et al 2013[@CIT0064]One 27-year-old maleCAN150 mg every 3--6 weeks for 8 injectionsNRYesNRTekin B et al 2017[@CIT0065]One 27-year-old maleINF, CANINF 5 mg/kg for 8 sessions, CAN 150 mg every 4 weeks for 3 dosesNRSlight improvement with INF, worsening with CANWorsening of HS with CANZangrilli A et al 2008[@CIT0117]One 32-year-old maleETA50 mg 2x/week for 24 weeks, then 25 mg 2x/week for 24 weeks48 weeksYesNoneTursi A 2016[@CIT0054]One 42-year-old femaleGOL200 mg once then 100 mg every 4 weeksNRYesNoneRoussomoustakaki M et al 2003[@CIT0038]One 29-year-old femaleINF5 mg/kg at 0, 2 and 6 weeks6 weeksYesNoneAdams DR et al 2003[@CIT0118]One 17-year-old maleINF5 mg/kg at 0, 2, 6 weeks, and 7 months7 monthsYesNoneRosi YL et al 2005[@CIT0119]One 30-year-old femaleINF5 mg/kg at 0, 2 and 6 weeks6 weeksYesNoneHusein-ElAhmed H et al 2011[@CIT0120]One 47-year-old maleINF4.6 mg/kg at weeks 0, 2, 6, 1010 weeksYes, but recurrence in 2 weeksNonevon Preussen AC et al 2012[@CIT0121]One 42-year-old femaleINF5 mg/kg at 0, 2 and 6 weeks and then every 8 weeksNRYesNoneMontes-Romero JA et al 2008[@CIT0037]One 39-year-old maleINF5 mg/kg at weeks 0,\
2, 6 and 14NRYesNoneGoertz RS et al 2008[@CIT0041]One 54-year-old maleINF5 mg/kg for 7 infusions2 yearsYes, but effect plateauedNew superinfectionBlazquez I et al 2013[@CIT0039]One 50-year-old femaleINFINF 5 mg/kg at 0, 2 and 6 weeks and then every 8 weeks6 monthsYesNoneGroleau PF et al 2015[@CIT0040]One 51-year-old maleINFI5 mg/kg at 0, 2 and 6 weeks and then 7.5 mg/kg every 8 weeks for 1 year, then 5 mg/kg every 8 weeks twice, then 2.5 mg/kg every 8 weeks twice\
Stopped for 7 months, then 5 mg/kg every 8 weeks when relapsedNRYes, relapsed after cessationNoneMartínez F et al 2001[@CIT0042]One 30-year-old maleINF5 mg/kg for 2 dosesNRYesGeneralized erythema and dyspneaLebwohl B et al 2003[@CIT0122]One 21-year-old maleINFNRNRYes, but recurred on prolonged sittingNoneThielen AM et al 2006[@CIT0123]One 48-year-old maleINF5 mg/kg at 0, 2 and 6 weeks then every 8 weeks104 weeksYesLimited herpes zosterGori A et al 2012[@CIT0044]One 19-year-old maleINF5 mg/kg at 0, 2 and 6 weeks then every 8 weeks14 weeksYesAcneAlecsandru D et al 2010[@CIT0124]One 47-year-old maleINF5 mg/kg at 0, 2 and 6 weeks then every 8 weeksNRYes, flared upon stoppingNonePoulin Y et al 2009[@CIT0125]One 25-year-old femaleETA, INFETA 50 mg twice a week, INF 5 mg/kg at 0, 2 and 6 weeks then every 6 weeks26 months of ETA, 20 months of INFWorsened with ETA, improved with INFETA caused flare of HSStaub J et al 2015[@CIT0036]One 22-year-old femaleETA, ADA, ANK, INFETA, ADA and ANK NR, INF 5 mg/kg at 0 and 2 weeks then every 8 weeks10 months of ETA, 5 months of ADA, 20 months of INF\
Not stated for ANKImproved with INF in combination with dapsone, steroids and cyclosporine but relapsed on tailing cyclosporineNoneOzer I et al 2016[@CIT0035]One 43-year-old maleINF5 mg/kg at 0, 2 and 6 weeks then every 8 weeks2 yearsYesNoneKozub *P* et al 2012[@CIT0126]One 53-year-old femaleINF500 mg at 0, 2 and 6 weeks then every 8 weeks43 weeksInitial improvement but plateaued until addition of dapsoneNoneVossen MG et al 2011[@CIT0043]One 21-year-old maleETA, INFETA 50 mg/week, INF 5 mg/kgNRNR*Gemella morbillorum* bacteremiaTakahashi H et al 2017[@CIT0095]One 19-year-old maleRIT200 mg for 2 doses 1 year apart1 yearYesNoneThorlacius L et al 2017[@CIT0074]One 47-year-old maleADA, INF, ANK, SECADA, INF, ANK NR, SEC 300 mg/week for 4 weeks then every 4 weeks after7 yearsNot improved with ADA, INF, ANK. Responded to SECOral candidiasis (SEC)Schuch A et al 2017[@CIT0075]One 24-year-old maleADA, INF SECADA, INF NR, SEC 300 mg/week for 4 weeks then every 4 weeks afterNRNot improved with ADA and INF, responded to SECNoneGiuseppe *P* et al 2018[@CIT0127]One 37-year-old maleINF, SECINF 5 mg/kg, SEC 300 mg/week for 4 weeks then every 4 weeks afterNRPartial improvement with INF, improved with SECNoneJørgensen AR et al 2018[@CIT0128]One 36-year-old femaleINF, ADA, UST, SECINF, ADA, UST NR, SEC 300 mg/week for 5 weeks then every month1 yearNo response to INF, ADA, UST, improved with SEC but small relapseThroat infections, feverSantos-Pérez MI et al 2014[@CIT0129]One 50-year-old femaleADA, USTADA 80 mg, then 40 mg every 2 weeks, UST 45 mg at weeks 0, 4 and then every 12 weeks2 years of ADA, 1.5 years of USTStable then worsened on ADA, improved with UST but 2 exacerbations reportedNoneSharon VR et al 2012[@CIT0130]One 55-year-old maleADA, USTADA NR, UST 45 mg at weeks 0, 4 and 12, then 90 mg every 8 weeksNRDid not respond to ADA, improved with UST but flares 2 weeks prior to next doseNoneScheinfeld N 2014[@CIT0045]One 47-year-old maleINF500 mg for 3 coursesNRNRMetastatic cutaneous squamous cell carcinoma**Case seriesStudySubject characteristicsTherapiesDoseTreatment durationEfficacyComplications**Blanco R et al 2009[@CIT0131]Six patients, two males and four femalesADA in six, ETA in oneADA 40 mg EOW, increased to weekly if inadequately controlled, decreased to 3-weekly if in remissionMean of 21.5 monthsETA ineffective, ADA effectivePain at injection site, severe facial cellulitis in one patientChinniah N et al 2014[@CIT0132]Six patients, four males and two femalesADA in three cases, INF in four cases, ETA in one case\*\*NRMean 25.3 monthsSignificant response to ADA in two, INF in three, ETA in oneNeurological adverse events in one patient on ADAHouriet C et al 2017[@CIT0063]Two (One male, one female)CANOne given 150 mg monthly, one given 150 mg on day 1 and 15 and then monthlyOne for 26 months, one for 12 monthsReduction in Sartorius score and VAS for both patientsNoneSun NZ et al 2017[@CIT0062]Two femalesCAN and ANK in one, ADA, INF and CAN in oneINF 5 mg/kg at week 0, 2 and 6, CAN 150 mg every 8 weeks, ANK 100 mg daily for first patient, ADA 40 mg weekly, INF 6 mg/kg and CAN 150 mg weekly for second patientNRINF effective in one patient, ADA partial response in same patientINF - hypersensitivity reaction in first patient, suspicion of drug-related interstitial nephritis in second patientSand FL et al 2015[@CIT0056]29 patientsADA in 22, ETA in five, INF in six, CER in two\*\*ADA 40 mg once weekly, ETA 50 mg once weekly, INF 5 mg/kg every 8 weeks, ADA 40 mg once weeklyMean of 13 months (1--50 months)12 out of 22 responded to ADA, two of five to ETA, one of six to INF, none of two for CERADA -- Meningealia, headache, fever in one patient, pneumonia in two patients, visual disturbances and headache in one patient; ETA -- urosepticemia in one patient, sebopsoriasis in one patient; INF --sensory and motor polyneuropathy, myalgia and arthralgia in one patient, recurrent tonsillitis in one patientZhao CY et al 2018[@CIT0021]Four malesADANR10--60 months50--100% improvementOne with development of melanoma in situ, one with worsening of Charcot-Marie-Tooth syndrome, one with drug-induced lupusPatil 2018[@CIT0133]Two malesADA biosimilar (ZRC-3197)40 mg weekly for 3 weeks, then EOW for 3 months3 months and 3 weeks\>50% reduction in abscess and inflammatory nodule count in both patientsNoneMenis et al 2014[@CIT0103]Two malesANK100 mg daily12 weeksNoOne with worsening of HSCusack et al 2006[@CIT0134]Six femalesETA25 mg twice weekly17--40 weeksAll six improved, between 44% and 73% in DLQI reductionIncreased frequency of upper respiratory tract infections in one patientLasocki et al 2010[@CIT0135]Four (One male, three female)INF5 mg/kg at week 0, 2 and 6, then 8-weekly maintenance infusions.38--54 weeksImprovement in all patients, but with recurrence in all after cessation of therapyHeadache and vomiting in one patientLozeron et al 2009[@CIT0020]One maleINF5 mg/kg at 0, 2, 6, 12 and 18 weeks18 weeksNot effectiveLewis-Summer Syndrome (demyelinating neuropathy)Elkjaer et al 2008[@CIT0136]Two malesINF5 mg/kg/day at 0, 2 and 6 weeks and then 5 weeklyNREffectiveInfusion reactions in one patientAntonucci et al 2008[@CIT0137]Two (one male, one female)INF5 mg/kg on weeks 0, 2 and 6 and then every 8 weeks59 weeksEffective in one, ineffective in oneNoneDelage et al 2011[@CIT0032]Seven (Three males, Four females)INF5 mg/kg on weeks 0, 2 and 6 and then every 8 weeks6--110 weeksEffective in sixOne with eczema-like eruption, one with pretragian abscessBrunasso et al 2008[@CIT0138]Seven (Three males, four females)INF5 mg/kg on weeks 0, 2 and 6 and then every 8 weeksMean 58.6 weeks (4--72)Improvements in pain, discharge, area reduction and DLQI. 3 with new lesions during therapyOne with adverse drug reaction, not further specifiedMoschella 2007[@CIT0139]Three (One male, two females)INF5 mg/kg on weeks 0, 2 and 6 and then varying subsequent dosing54--80 weeksEffective in allNoneSullivan et al 2003[@CIT0140]Five (One male, four females)INF5 mg/kg at week 0 for all five patients, and again at week 4--6 for three patients0-- 6 weeksEffective in allPresumed *Mycobacterium tuberculosis* lymph node infection in one patientTorres et al 2010[@CIT0141]Two patientsINF5 mg/kg on weeks 0, 2 and 6 and then every 8 weeks7 monthsIneffectiveNoneUsmani et al 2006[@CIT0142]Four patients (two males, two females)INF5 mg/kg, varying dosingUp to 11 monthsTwo with good response, one with mild response, one with poor responseOne with INF-induced lupus, one with infusion reactionFernández-Vozmediano et al 2007[@CIT0143]Six patients (Two males, four females)INF5--10 mg/kg at weeks 0, 2 and 6, then every 4 weeks6 monthsImprovement to stage I in four cases, stage II in two casesOne with headacheMoriarty et al 2014[@CIT0031]11 patients (Eight males, three females)INF5--10 mg/kg at weeks 0, 2 and 6, then every 4 to 8 weeksMedian 49.1 monthsAll with initial improvement, two with secondary failureNine cutaneous infections requiring antibiotics, four respiratory tract infections requiring antibiotics, one episode of tonsillitis requiring antibiotics, one case of Hodgkin lymphoma 36 months after cessation of INFKovacs et al 2018[@CIT0084]Three (Two males, one female)GUS100 mg at weeks 0 and 4, then 8 weeklyAt least 12 weeksImprovements in IHS4, VAS and DLQI at 12 weeks in all patientsNoneWeber et al 2017[@CIT0088]Nine patients (Six males, three females)APR30 mg twice daily2 days to 9 monthsImprovement in five of six who persisted with therapyTwo with weight loss, one with loose stool, one with dry cough, one with nausea, one with refluxZhang et al 2014[@CIT0144]22 (nine males, 13 females)15 on INF, seven on ADANR1 month to 3 years14 with improvement (11 with INF, three with ADA)Three with infusion reactions, two with fatigue, one with anaphylaxis, one with heart failure, one with dyspnea, one with recurrent HSV. One death from lung malignancy, one death from metastatic perianal squamous cell carcinoma (both on INF) but no direct causal relationship established.DeFazio et al 2016[@CIT0145]11 patientsEight on INF, three on USTMean 10.5 months (6 to 15 months)NREffective in seven, local recurrence in four, of which one was after 4 months of INFNoneMonné et al 2014[@CIT0146]Four patientsFour on ADA, of which one also tried INF and ETAVarying dosesNRADA effective in three of four, ETA and INF ineffectiveNoneGulliver et al 2011[@CIT0147]Three (one male, two female)UST45 mg at 0, 1 and 4 months6 monthsOne ineffective, one 25--49% disease clearance, one complete clearanceOne patient with *S. aureus* of right axilla, one patient with cystitis, psoriasiform dermatitis and arthritis**Retrospective analysesStudySubject characteristicsTherapiesDoseTreatment durationEfficacyComplications**van Rappard et al 2012[@CIT0148]30 patients (17 males and 13 females)INFWeeks 0, 2 and 6 and\
subsequently every 8 weeks.Mean 9.3 months10 free of lesions, 13 improved, 4 moderately improved, 3 no responseNoted in 12 patients, not further specifiedMartin-Ezquerra G et al 2014[@CIT0149]19 patients (ten males, nine females)ADA in 11 cases, INF in ten cases, UST in two cases, ETA in two cases\*\*NRMean of 12 monthsPhysician-judged at least partial responses for ADA in eight, INF in seven, UST in three, none for ETASevere infusion reaction and hypertriglyceridemia in two patientsBettoli, Manfredini et al 2018[@CIT0150]34 patients (19 males, 15 females)ADANRVarying, up to at least 1 yearAmong group receiving ADA for \>1 year, 60% achieved HiSCR at 3 months and maintained up to 12 months.NRKyriakou et al 2018[@CIT0151]19 (five males, 14 females)ADA160 mg at week 0, 80 mg at week 2, 40 mg at week 4 and 40 mg weekly afterAt least 24 weeks63.1% achieved clinical response at 24 weeks (defined by HS-PGA score of clear, minimal or mild with at least two-grade improvement from baseline).None^\#^Casseres et al 2018[@CIT0085]Eight (five males, three females)GUS100 mg at week 0, 4 and then 8 weeklyUp to 10 monthsFive (63%) with improvementNone**Cohort studiesStudySubject characteristicsTherapiesDoseTreatment durationEfficacyComplications**van Rappard et al 2011[@CIT0152]19 patients (12 males, seven females)Ten on INF, nine on ADAINF 5 mg/kg at weeks 0, 2 and 6. ADA 40 mg EOW.6 weeks46% reduction in Sartorius score in INF group vs 34% in ADA groupOne on INF with acute arthritis and myalgia, three on ADA with fatigue, one with injection site painSbidian et al 2016[@CIT0153]67 patients (30 males, 37 females)17 on ADA, 63 on ADA, eight on ETA\*\*INF 5 mg/kg, ADA 40 mg EOW, ETA 50 mg twice a weekNRTreatment with ADA associated with at least partial response compared to ETA or INF with hazards ratio of 6.6 (*p*=0.001)One each with hepatitis, lupus, repeated urinary tract infection and pulmonary embolismShanmugam et al 2018[@CIT0112]68 patients (23 males, 45 females; 31 ever had biologics, 37 never had biologics)NRNRNREver receiving biologics associated with sharper decline in HS activity, biologic use associated with significant reduction in HSS and Hurley stage, effect of biologics greater in patients who received surgery, combination therapy with surgery and biologics associated with higher probability of achieving 75% reduction in active nodule count.NRClinical trials**StudyTrial characteristicsSubject characteristicsTherapiesDoseTreatment durationEfficacyComplications**Kimball et al 2016,[@CIT0012] Zouboulis et al 2018[@CIT0015]Randomized double-blind placebo-controlled Phase III trial, with open-label extension to 168 weeks307 for PIONEER I, 326 for PIONEER IIADA40 mg weekly vs 40 mg EOW vs placebo36 weeksMore patients in the weekly ADA group achieved HiSCR \[41.8% versus 26.0% in PIONEER I (*p*=0.003) and 58.9% vs 27.6% in PIONEER II (*p*\<0.001)\]. Mean duration of infection-free HiSCR was significantly longer in ADA compared to placebo group (*p*\< 0.001).[@CIT0154] More patients on ADA achieved a ≥30% in the Patient's Global Assessment of Skin Pain, both PIONEER I (ADA \[40.3%\] vs placebo \[24.9%\]; OR =2.03, *p*=0.004) and II (ADA \[61.2%\] vs placebo \[24.8%\]; OR=4.78, *p*\<0.001).[@CIT0155] Achievement of HiSCR was maintained through week 168 in 52.3% in weekly ADA group\
and 57.1% of responders plus partial responders.[@CIT0015]Among ADA group, new psoriasiform eruptions and psoriasis in ten patients, one case of squamous cell carcinoma of the nose, and one death from cardiorespiratory arrest 42 days after the last dose of ADA in a 35-year-old man with a history of diabetes mellitus, smoking and a family history of ischemic heart disease. Adverse events observed during open-label extension were similar to safety profiles observed in PIONEER studies.[@CIT0015] Safety analysis of every week and EOW dosing showed similar adverse event rates.[@CIT0016]Jiménez-Gallo et al 2018[@CIT0156]Prospective open label study19 (11 males, eight females)ADA40 mg weekly36 weeksHiSCR in 68.42%.NRKimball et al 2012[@CIT0011]Phase II parallel randomized, placebo-controlled trial with a blinded 16-week period and an open-label 36-week period154ADA40 mg weekly vs 40 mg EOW vs placebo52 weeks17.6% in weekly ADA vs 9.6% in EOW group vs 3.9% in placebo group achieved HS-PGA score of clear, minimal, or mild with at least a two-grade improvement relative to baseline score at week 16 (EOW vs placebo difference, 5.6% \[95% CI, 4.0% to 15.3%\]; *p* 0.25; weekly vs placebo difference, 13.7% \[CI, 1.7% to 25.7%\]; *p* 0.025). Proportion with clinical response decreased after change from weekly to EOW dosing. A shorter time to achieving HiSCR in weekly ADA vs EOW group.[@CIT0099]24 listed serious adverse events: rectal fissure, inadequately controlled diabetes mellitus, goiter, hidradenitis, interstitial lung disease, pilonidal cyst, viral infection, anemia, bacteremia, vocal cord neoplasm, bacterial genital infection, Escherichia infection, penile swelling, purulent discharge, pustular rash, scrotal swelling, noncardiac chest pain, and cellulitis.Arenbergerova et al 2010[@CIT0157]Open label trialEight (three males, five females)ADA80 mg at week 0, 40 mg at week 1, then 40 mg EOW12 monthsMean reduction in pain and discharge of 86.5% and 72.8% respectively at 12 months, and 56.6% and 50.1% at 24 monthsOne case of EBV infectionAmano et al 2010[@CIT0101]Open-label Phase II trialTen, of which six completed treatmentADA160 mg at week 0, 80 mg at week 1, 40 mg EOW12 weeksNone responded, as defined by at least 50% decrease in HSSI scoreNo serious adverse eventsLeslie et al 2014[@CIT0060]Open-label trial6 (Two males, four females), of which five completed the studyANK100 mg daily8 weeksSignificant improvement in modified Sartorius score during treatment and rebound during follow-up post-treatmentNoneTzanetakou et al 2016[@CIT0058]Randomized double-blind placebo-controlled trial20 patients (ten in anakinraANK arm, ten in placebo arm), of which 19 completed studyANK100 mg daily12 weeksAt week 12, 78% in ANK arm vs 20% in placebo arm had reduction in disease activity score, defined as the sum of scores of all affected areas (two largest diameters in each affected areas multiplied by degree of inflammation at each lesion), and 78% vs 30% achieved HiSCR. At week 24, 10% vs 33% achieved HiSCR.No serious adverse eventsVossen et al 2018[@CIT0089]Randomized double-blind placebo-controlled trial20 (15 given apremilastAPR and five given placebo) of which 18 completed the studyAPR30 mg BD16 weeksEight of 15 achieved HiSCR in APR arm compared to none in placebo arm (*p*=0.055) at week 16.38 adverse events in APR arm vs 11 in placebo arm, none categorized as severe.Cusack et al 2006[@CIT0134]Open-label trialSixETA25 mg twice weekly17 to 40 weeks44 to 73% reduction in DLQI 12 to 24 weeks after starting treatmentIncreased incidence of URTIs in one patientGiamarellos-Bourboulis et al 2007[@CIT0047]Open-label Phase II trialTen three males, seven females)ETA50 mg weekly12 weeks\>50% decrease in disease activity (defined as sum of lesions with each lesion evaluated with the formula: lesion diameters multiplied by severity) in six patients at week 12 and seven patients at week 24.No serious adverse events: three patients with self-limited injection site erythema, one patient with right gluteal abscessSotiriou et al 2008[@CIT0050]Open- label trialFour (one male and three females)ETA25 mg twice a week6 months54--73% reduction in DLQIOne case of mild injection site reactionLee et al 2009[@CIT0049]Open-label trial15, of which ten completed treatmentETA50 mg weekly for 12 weeks, then 25 mg weekly for 2 weeks14 weeksOnly three (20%) of patients achieved 20% reduction in PGA, based on intention to treat analysis.No serious adverse events reportedPelekanou et al 2010[@CIT0048]Open-label Phase II trialTenETA50 mg weeklyInitial 12-week duration, then subsequent 0 to 96-week course depending on recurrenceThree who improved in mSS with no recurrence and 7 who improved and then recurred after stopping treatment, of which five had a positive response to repeat treatmentNoneAdams et al 2010[@CIT0051]Randomized trial with 12-week double-blind placebo-controlled phase followed by 12-week open-label phase20 patients (ten in etanerceptETA arm and ten in placebo arm), of which 14 completed entire studyETA50 mg twice weekly24 weeksNo statistically significant difference in physician global assessment between treatment and placebo armsNo serious adverse eventsParadela et al 2012[@CIT0033]Open-label trialTen (four males, six females)INF5 mg/kg at week 0, 2, 6 and then 8-weekly29 to 181 weeksEight with response (defined as 50% reduction in hidradenitis severity score), of which four relapsed (defined as 40% increase in score of initial response)One case of mycobacterial folliculitis, one case of scrotal abscess, two cases of psoriasis, five cases of positive anti-nuclear antibodies, two cases of transient hyperlipidemiaGrant et al 2010[@CIT0009]Clinical trial with 8-week double-blind placebo-controlled phase followed by 14- to 22-week open label phase38 patients (15 in infliximabINF arm and 23 in placebo arm)INF5 mg/kg at week 0, 2 and 6 and then 8 weekly22 weeksAt week 8, 60% of patients in INF arm vs 5.6% of patients in placebo arm had 25% to less than 50% reduction in HSSI, and 13.3% of patients in INF arm vs 88.9% in placebo arm had less than 25% decrease in HSSI (*p*\<0.001).Serious adverse events: one pregnancy, one case of hypertension, one infusion reaction requiring hospitalization.Mekkes et al 2007[@CIT0034]Open-label trial11, of which ten (four males, six females) completed the studyINF5 mg/kg at week 0, 2 and 66 weeksImprovements in all patients within 2--6 weeks, as defined by reduction in mSS. At one year, improvements in 6 patients, but recurrences in 4.One with numbness and pain in both legs, one with anaphylactic shock, and one with myalgia and feverKanni et al 2018[@CIT0066]Randomized double-blind placebo-controlled trial20 patients (10 in bermekimabBER arm and 10 in placebo arm)BER7.5 mg/kg every 14 days12 weeks60% in BER arm vs 10% in placebo arm achieved HiSCR at week 12, and 40% vs 0% at week 24.19 HS exacerbations in BER group, of which 2 required hospitalizationBlok et al 2016[@CIT0072]Open-label trial17 (four males, 13 females)USTWeek 0, 4, 16 and 28--45 mg per dose for participants weighing \<100 kg and 90 mg per dose for those \>100 kg28 weeksMarked improvement of mSS in six (35%), moderate in eight (47%), mild in one (6%), no change/worsening in two (12%) at 40 weeks. Mean mSS of intention-to-treat population decreased from 112.12 to 60.18 at week 40 (46.33% improvement, *p*\<0.01). Eight (47%) achieved HiSCR at week 40.Headache, fatigue, URTIGuo et al 2017[@CIT0091]Open-label phase II trial12IFX-1800 mg on days 1, 4, 8, 15, 22, 29, 36, 43 and 5050 days83% achieved HiSCR at Day 134 (95% CI: 0.52--0.98).NR[^7]

TNF-α inhibitors {#S0006-S2001}
----------------

### Adalimumab {#S0006-S2001-S3001}

Adalimumab is a recombinant human anti-TNF-α IgG1 monoclonal antibody. When used for HS, it is given subcutaneously as an initial dose of 160 mg, followed by a dose of 80 mg 2 weeks later, and a maintenance dose of 40 mg weekly thereafter.[@CIT0010] In 2015, it became the first and, to date, only FDA-approved biologic agent for the treatment of moderate/severe HS.[@CIT0010]

A Phase II study by Kimball et al in 2012 first demonstrated that a significantly greater proportion receiving adalimumab weekly (17.6%) compared to placebo (3.9%) achieved the primary clinical endpoint of a HS-PGA score of clear, minimal or mild with at least a two-grade improvement relative to baseline scores at week 16. This effect was not significantly demonstrated in the group of patients receiving adalimumab every other week (9.6%) (weekly vs placebo difference 13.7%, *p*=0.025; every other week vs placebo difference 5.6%, *p*=0.25).[@CIT0011] After changing from weekly to every other week dosing, a decreased proportion of patients showed a clinical response.[@CIT0011]

The subsequent PIONEER I and II Phase III trials involved a total of 633 patients with moderate-to-severe HS with an inadequate response to oral antibiotics. A significantly higher proportion of patients given adalimumab achieved HiSCR, compared to patients given placebo after 12 weeks of treatment (PIONEER I: 41.8% vs 26.0%, *p*=0.003; PIONEER II: 58.9% vs 27.6%, *p*\<0.001).[@CIT0012] Most adverse events observed were mild or moderate in severity. Of note, in the group of patients treated with adalimumab, there were new psoriasiform eruptions and psoriasis in ten patients, one case of squamous cell carcinoma of the nose, and one death from cardiorespiratory arrest 42 days after the last dose of adalimumab in a 35-year-old man with a history of diabetes mellitus, smoking and a family history of ischemic heart disease.[@CIT0012] Secondary efficacy data also showed a greater proportion of subjects achieving a ≥30% reduction in the Patient's Global Assessment of Skin Pain (PGA-SP) in both PIONEER I (adalimumab vs placebo \[24.9%\]; OR=2.03, *p*=0.004) and PIONEER II (adalimumab \[61.2%\] vs placebo \[24.8%\]; OR=4.78, *p*\<0.001).[@CIT0013],[@CIT0014]

An open-label extension trial of the PIONEER I and II trials also confirmed that patients who continued to receive weekly adalimumab maintained a long-term response with a HiSCR rate of 52.3% at week 168 and a decrease in the Dermatology Life Quality Index (DLQI) of 5.1--6.8 points at week 72, with no new safety risks identified.[@CIT0015]

In a study by Ryan et al that analyzed the safety data of adalimumab in HS, there were no new safety concerns identified with the weekly dosing of adalimumab compared with every other week dosing.[@CIT0016]

In case reports, adalimumab has also shown effectiveness in treating HS associated with pyoderma gangrenosum, acne and psoriatic arthritis.[@CIT0017]--[@CIT0019] However, some case reports and series have drawn caution to the use of adalimumab, reporting adverse events such as erythroderma, melanoma, demyelinating disorders and drug-induced lupus.[@CIT0020]--[@CIT0022]

There are currently post-marketing surveillance trials of adalimumab underway, assessing quality of life, effectiveness of treatment and safety profile.[@CIT0023]--[@CIT0027] In addition, the safety, efficacy and cost-effectiveness of adalimumab in conjunction with surgery are currently under investigation by two Phase IV trials.[@CIT0028],[@CIT0029]

### Infliximab {#S0006-S2001-S3002}

Infliximab is a chimeric mouse/human anti-TNF-α monoclonal antibody. It is currently FDA-approved for use in inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis;[@CIT0030] and has been used as an off-label treatment in patients with HS resistant to adalimumab.[@CIT0009],[@CIT0031],[@CIT0032] It is currently dosed as an intravenous infusion 5 mg/kg body weight on week 0, 2, 6 and thereafter every 8 weeks.[@CIT0030] However, reports suggest that the dosing regimen for HS requires further refinement.[@CIT0031]

In a descriptive single-center study involving 10 patients, no long-term curative effect was uniformly seen.[@CIT0033] In another study evaluating the efficacy of a single course (three infusions) of infliximab in 10 patients, three patients did not have a recurrence at 2 years, whereas the other seven had an average time of 8.5 months to recurrence of lesions (4.3--13.4 months).[@CIT0034]

In a Phase II randomized study comprising a double-blind placebo-controlled treatment phase, an open-label crossover treatment phase and an observational phase, 38 patients with moderate-to-severe HS as defined by a HSSI score \>8 were selected. More patients treated with regular infliximab responded with a 25% to \<50% decrease in HSSI compared to placebo (60% vs 5.6%), whereas most patients treated with placebo had a \<25% decrease in HSSI compared with infliximab (88.9% vs 13.3%, *p*\<0.001).[@CIT0009] After 8 weeks of treatment, there were significant improvements in the infliximab group compared to the placebo group in terms of mean DLQI change (−10 vs −1.6, *p*=0.003) and mean PGA scores (1.8 vs 4.7, *p*\<0.001).[@CIT0009] Most adverse events were mild and none were considered unexpected.[@CIT0009]

In case reports, infliximab demonstrated efficacy in treating HS associated with pyoderma gangrenosum, acne, Crohn's disease and systemic amyloidosis.[@CIT0035]--[@CIT0042]

However, infliximab has also in cases been associated with paradoxical worsening of facial acne vulgaris, demyelinating neuropathies, metastatic cutaneous squamous cell carcinoma and a case of *Gemella morbillorum* bacteremia complicated by brain abscesses.[@CIT0020],[@CIT0043]--[@CIT0045]

### Etanercept {#S0006-S2001-S3003}

Etanercept is a dimeric TNF-α inhibitor. It is approved for use in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, plaque psoriasis and psoriatic arthritis.[@CIT0046]

After showing mixed results in open-label trials,[@CIT0047]--[@CIT0050] it was examined under a double-blind, placebo-controlled study in 20 patients with moderate-to-severe HS. In patients given etanercept 50 mg twice weekly for 24 weeks, no significant improvement in HS was found.[@CIT0051]

### Golimumab {#S0006-S2001-S3004}

Golimumab is an anti-TNF-α human monoclonal antibody, approved for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.[@CIT0052]

To date, it has been used in two case reports in the treatment of HS. In a case of a patient with concomitant Hurley Stage 3 HS and psoriatic arthritis, the use of subcutaneous golimumab 50 mg once weekly did not result in clinical improvement of HS (after adalimumab and anakinra had failed).[@CIT0053] However, in a later case report published in 2016 of a 42-year-old female with Hurley Stage 2 HS and pyostomatitis vegetans on a background of ulcerative colitis, golimumab subcutaneously 200 mg once followed by 100 mg every 4 weeks, together with amoxicillin-clavulanate, resulted in complete and sustained remission of HS, pyostomatitis vegetans and ulcerative colitis.[@CIT0054]

There are no clinical trials underway to further assess golimumab in HS.

### Certolizumab {#S0006-S2001-S3005}

Certolizumab is a PEGylated Fab fragment of a humanized TNF-α monoclonal antibody that is FDA-approved for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis.[@CIT0055] Its use in HS was described briefly in a case series, where it was used in two patients but found to be ineffective.[@CIT0056]

IL-1 inhibitors {#S0006-S2002}
---------------

### Anakinra {#S0006-S2002-S3001}

Anakinra is a recombinant IL-1 receptor inhibitor which is FDA-approved for use in rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.[@CIT0057] It has been given as a 100 mg subcutaneous daily dose in HS.[@CIT0057]

It has been studied in a double-blind, randomized, placebo-controlled Phase II clinical trial involving 20 patients. There were significantly more patients with a decreased disease activity score in the anakinra group compared to the placebo group after 12 weeks of treatment (78% vs 20%, *p*=0.02) and achieving HiSCR at the end of 12 weeks (78% vs 30%, *p*=0.04).[@CIT0058] However, at 24 weeks, the difference in patients achieving HiSCR was not statistically significant (10% vs 33%, *p*=0.28).[@CIT0058]

In later case reports, there were also experiences of failure of anakinra therapy, or even worsening of HS related to anakinra use, suggesting the need for further clinical trials.[@CIT0059] Painful injection site reactions are also commonly reported with the use of anakinra, limiting its tolerability for some patients.[@CIT0060] It was also linked with drug-induced sarcoidosis in one case report.[@CIT0013]

### Canakinumab {#S0006-S2002-S3002}

Canakinumab is a human monoclonal anti-IL-1β antibody which is FDA-approved for use in cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis.[@CIT0061] It has been given up to 150 mg subcutaneous weekly dose in the treatment of HS. To date, it has shown mixed results in case reports and series.[@CIT0062]--[@CIT0065]

### Bermekimab {#S0006-S2002-S3003}

Bermekimab (MABp1) is an anti-IL 1α human monoclonal antibody. In a recent Phase II trial involving 20 patients with moderate-to-severe HS either randomized to bermekimab or placebo for 12 weeks, 60% of patients on bermekimab achieved HiSCR at week 12 compared to 10% on placebo (*P*=0.035).[@CIT0066] Twelve weeks after cessation of treatment, 40% of patients on bermekimab had a positive HiSCR compared to 0% of patients on placebo.[@CIT0066] No adverse events related to bermekimab were reported.[@CIT0066]

### MEDI8968 {#S0006-S2002-S3004}

MEDI8968 is a fully human immunoglobulin monoclonal antibody that selectively binds to the IL-1R1 receptor to inhibit activation by IL-1α and IL-1β. It has been studied for use in osteoarthritis, rheumatoid arthritis and chronic obstructive pulmonary disease.[@CIT0067]--[@CIT0069] A Phase IIa study evaluating the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate-to-severe HS was terminated early due to a lack of efficacy.[@CIT0070]

IL-12/-23 inhibitors {#S0006-S2003}
--------------------

### Ustekinumab {#S0006-S2003-S3001}

Ustekinumab is a human monoclonal antibody that acts by binding to and inhibiting the p40 subunit on IL-12 and IL-23. It is FDA-approved for use in plaque psoriasis, psoriatic arthritis and Crohn's disease.[@CIT0071] Patients weighing 100 kg and below receive 45 mg per dose, and those weighing above 100 kg receive 90 mg per dose.[@CIT0071]

In a Phase II open-label study involving 17 patients on ustekinumab, the majority of patients showed moderate to marked improvement, as defined by a significant decrease in the mSS and modified HS Lesional Area Severity Index.[@CIT0072] Forty-seven percent of patients achieved HiSCR.[@CIT0072] Adverse events were mild and temporary, most commonly headache, fatigue and upper respiratory tract infections. The authors of the Phase II study suggested that the dosing regimen in HS may have to be further intensified.[@CIT0072]

IL-17 inhibitors {#S0006-S2004}
----------------

### Secukinumab {#S0006-S2004-S3001}

Secukinumab is a human IgG1k monoclonal antibody that acts as an IL-17A inhibitor. It is FDA-approved for moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.[@CIT0073] Given at 300 mg subcutaneously weekly for 1 month followed by 4-weekly maintenance dosing, it has shown dramatic improvement in case reports of patients in whom other biologic therapies failed.[@CIT0074],[@CIT0075] An exploratory pilot study on the safety and feasibility of secukinumab in HS patients is currently underway,[@CIT0076] and there are two randomized double-blind multicenter trials to compare the efficacy, safety and tolerability of 2-weekly and 4-weekly secukinumab 300 mg in patients with moderate-to-severe HS.[@CIT0077],[@CIT0078]

### CJM112 {#S0006-S2004-S3002}

CJM112 is a human monoclonal anti-IL-17A antibody. A Phase II study involving 66 patients with moderate-to-severe chronic -HS has been completed, but results are not available at present.[@CIT0079]

### Bimekizumab {#S0006-S2004-S3003}

Bimekizumab is a humanized anti-IL17A and IL-17F monoclonal antibody which has been studied and found to be effective in patients with psoriasis.[@CIT0080],[@CIT0081] A Phase II trial is currently underway to investigate its use in moderate-to-severe HS, with no results available at the time of writing.[@CIT0082]

IL-23 inhibitors {#S0006-S2005}
----------------

### Guselkumab {#S0006-S2005-S3001}

Guselkumab is an anti-IL-23 monoclonal antibody that has been FDA-approved for use in adults with moderate-to-severe plaque psoriasis. It is given subcutaneously 100 mg at week 0, week 4 and every 8 weeks thereafter.[@CIT0083] A case series involving three patients with severe HS, given guselkumab, found significant reductions in the IHS4, VAS for pain and (DLQI for all three patients.[@CIT0084] Another retrospective chart review of eight patients with moderate-to-severe HS given guselkumab found that 63% of patients reported improvements, with suggestions to further intensify the dosing regimen.[@CIT0085] No adverse events were documented in both articles. A Phase II multicenter randomized double-blind placebo-controlled trial has been initiated to evaluate its efficacy in the treatment of moderate-to-severe HS.[@CIT0086]

Selective PDE-4 inhibitors {#S0006-S2006}
--------------------------

### Apremilast {#S0006-S2006-S3001}

Apremilast is an orally administered PDE-4 inhibitor which is FDA-approved for use in patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis. It is titrated to a target dose of 30 mg twice daily.[@CIT0087]

In a reported case series of nine patients with Hurley stages II--III HS who had responded poorly to other treatments, five of six patients who persisted with treatment showed a good clinical response, with a significant improvement in the Sartorius score (73.17±67.76 to 56.17±44.89, *p*=0.028), VAS (7.17±0.98 to 2.00±2.10, *p*=0.026) and DLQI (21.33±8.91 to 9.33±5.85, *p*=0.027).[@CIT0088]

In a double-blind, randomized, placebo-controlled trial involving 20 patients with moderate HS, 8 of 15 patients (53.3%) given apremilast achieved a positive HiSCR at week 16 compared to zero of five in the placebo group (*p*=0.055). Patients receiving apremilast also showed a significantly lower abscess and nodule count (mean difference −2.6; 95% CI −6.0 to −0.9; *p*=0.011), numerical rating scales for pain (mean difference −2.7; 95% CI −4.5 to −0.9; *p*=0.009), itch (mean difference −2.8; 95% CI −5.0 to −0.6; *p*=0.015) and disease burden (mean difference −1.8; 95% CI −3.7 to −0.01; *p*=0.049) compared to placebo. There were no major adverse events documented.[@CIT0089]

Another Phase II open-label trial involving 20 patients has been completed, with no results available at present.[@CIT0090]

Complement 5a inhibitors {#S0006-S2007}
------------------------

### IFX-1 {#S0006-S2007-S3001}

IFX-1 is a human C5a-specific monoclonal antibody. Preliminary data from an open-label clinical study involving 12 patients, 75% of patients achieved HiSCR at day 50 (95% CI 0.43--0.95) and 83% at day 134 (95% CI 0.52--0.98).[@CIT0091],[@CIT0092]

Another Phase II study is currently underway to determine its efficacy and safety.[@CIT0093]

CD-20 inhibitors {#S0006-S2008}
----------------

### Rituximab {#S0006-S2008-S3001}

Rituximab is a chimeric monoclonal antibody against the CD20 protein. It is FDA-approved for use in non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris.[@CIT0094]

In one case report in a kidney transplant recipient with idiopathic carpotarsal osteolysis who suffered chronic active antibody-mediated rejection and also developed HS, low-dose rituximab with two courses of 200 mg each were given with dramatic improvement of HS without remission of rejection.[@CIT0095]

There are no further studies underway to evaluate the efficacy of rituximab.

JAK-1 inhibitors {#S0006-S2009}
----------------

### INCB054707 {#S0006-S2009-S3001}

INCB054707 is an orally administered inhibitor of the Janus kinase 1 pathway. There are currently two Phase II trials underway, with no other information available at the time of writing.[@CIT0096],[@CIT0097]

Discussion {#S0007}
==========

The increased understanding of the inflammatory pathways in HS provides many exciting therapeutic opportunities for patients with HS resistant to conventional methods of therapy. As more molecular targets are identified, immunomodulatory therapies can be developed, and their dosing regimens further refined. The efficacy, or lack thereof, of individual therapies also provides key insights into disease pathophysiology.

TNF-α inhibition in HS has been demonstrated to be useful. Adalimumab is presently the only FDA-approved biologic for use in HS and should thus be the drug of choice in moderate-to-severe HS where conventional treatment has proven ineffective. It is worth noting from our systematic review that where HS is associated with pyoderma gangrenosum, acne, Crohn's disease or systemic amyloidosis, infliximab may also be considered as an effective off-label treatment.

Etanercept and MEDI8968 have already proven to be ineffective. Other therapies, involving smaller cohorts, have shown partial or mixed responses, with larger trials underway to further assess their efficacy in HS. The varying clinical measurement scores and endpoints used in these trials to determine treatment responsiveness potentially complicate direct comparison between different agents.

Most biologics and immunomodulatory therapies exhibit a generally well-tolerated safety profile. However, long-term safety concerns, including infection risks, especially latent tuberculosis reactivation, demyelinating disorders, and the development of malignancy from chronic immunosuppression will need to be evaluated through longitudinal surveillance and pooled registry data.[@CIT0098] These issues are especially pertinent in the treatment of HS, where the dosing regimen for biologics is typically more intensive compared to other inflammatory diseases, such as psoriasis. Patient selection remains important, as complete response is not the norm, not all patients with HS tolerate or respond well to immunomodulatory therapy, and may benefit from other modes of treatment, such as surgery.

In patients with severe HS that does not fully respond even to biologic treatment, we may consider biologics as an adjunct to surgery, where biologics are used to debulk disease to minimize the area required for surgical resection. Results from Phase IV trials to assess the combination of adalimumab with surgery will help refine the treatment approach for this category of severe HS.[@CIT0028],[@CIT0029]

Ultimately, it is hoped that the use of immunomodulatory therapies will help overcome some of the challenges in treating severe HS, alleviating the impact on sufferers' quality of life and morbidity associated with the disease. However, more quality data is required on their efficacy, safety and use in specific sub-populations before we can achieve truly targeted treatment of HS.
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[^1]: **Note:**Data from Hurley.[@CIT0008]

[^2]: **Abbreviation:** HS, hidradenitis suppurativa.

[^3]: **Abbreviations:** HiSCR, hidradenitis suppurativa clinical response; HS-PGA, HS physician's global assessment; mSS, modified sartorius score; HSSI, HS severity index; BSA, body surface area; IHS4, International HS Score System.

[^4]: **Notes:**^a^FDA-approved for treatment of HS

[^5]: ^b^No longer available, and thus excluded from further review.

[^6]: **Abbreviation:**HS, hidradenitis suppurativa.

[^7]: **Notes:** \*\*Overlapping due to switches in therapy. ^\#^Study excluded patients who discontinued treatment due to adverse event or had to receive another therapeutic modality.

    **Abbreviations:** ADA, adalimumab; GOL, golimumab; ANK, anakinra; ETA, etanercept; INF, infliximab; CAN, canakinumab; RIT, rituximab; SEC, secukinumab; UST, ustekinumab; CER, certolizumab; GUS, guselkumab; APR, apremilast; BER, bermekimab; EOW, every other week; NR, not reported; PASH, pyoderma gangrenosum, acne and suppurative hidradenitis; NSAID, non-steroidal anti-inflammatory drug; HPV, human papillomavirus; SAPHO, synovitis, acne, pustulosis, hyperostosis and osteitis; HCV, hepatitis C virus; Nd-YAG, neodymium-doped yttrium aluminum garnet; CO~2,~ carbon dioxide; IHS4, international HS severity score system; HSV, herpes simplex virus; HSS, HS score; HiSCR, HS clinical response; URTI, upper respiratory tract infection; PGA, physician global assessment; mSS, modified sartorius score; EBV, Epstein-Barr virus, HSSI, HS severity index.
